Cxbladder® Triage Plus

Cxbladder® Triage Plus is a non-invasive urine genomic test that measures the expression of five biomarker genes (CDC2, IGFBP5, HOXA13, MDK, CXCR2) to determine the likelihood of urothelial cancer. It is recommended in the 2020 American Urological Association (AUA) Microhaematuria Guideline as the first and only urine-based genomic biomarker test supported by Level A Evidence.

Patients presenting to urologic care with haematuria (visible or non-visible) requiring risk stratification to guide the need for cystoscopy. Suitable for use in primary care and urology settings to de-intensify work-up in low-risk patients.

30–50 mL midstream urine collected into the Cxbladder collection tube (contains preservative). Do not use catheter samples.

Available through Codex Genetics as the authorised Pacific Edge distributor in Hong Kong. Please contact us for test kits, collection instructions, and ordering.

Bladder cancer is the 10th most common cancer globally. Haematuria is the most common presenting symptom, but most patients with haematuria do not have bladder cancer. The AUA 2020 Microhaematuria Guideline recommends Cxbladder Triage Plus as a Level A Evidence urine biomarker test to risk-stratify patients and reduce unnecessary invasive investigations. The test analyses gene expression of IGFBP5, HOXA13, MDK, CDC2, and CXCR2.